![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Conventional anthracyclines represent a cornerstone drug in the treatment of breast cancer. Pegylated liposomal doxorubicin (PLD) has similar efficacy to anthracyclines with reduced toxicity. This study was to compare the efficacy and safety of PLD-based neoadjuvant chemotherapy (NAC) with epirubicin-based treatment for breast cancer. 81 breast cancer patients were enrolled in this retrospective study. The objective response rate (ORR) in the PLD group was 74.1%, the 3-year disease-free survival(DFS) and overall survival(OS) were 81.5% and 88.9%. The PLD group achieved similar efficacy to the EPI group. The PLD group showed a low rate of neutropenia , nausea and vomiting, but a higher rate of mucositis and hand-foot syndrome. In neoadjuvant chemotherapy for invasive breast cancer, PLD provides comparable efficacy to epirubicin with a safe cardiac toxicity profile and manageable adverse effects.
Additional information
Funding
Notes on contributors
Jia Yao
Yao Jia is responsible for overall query and writing this article.
Shaobo Pan
Pan Shaobo is responsible for the revision of the article and the production of charts.
Xiao Fan
Fan Xiao is responsible for the statistics and verification of the data.
Xue Jiang
Jiang Xue is responsible for answering radiotherapy related questions.
Yuhong Yang
Yang yuhong and Jin Jing are responsible for telephone follow-up and registration.
Jing Jin
Yang yuhong and Jin Jing are responsible for telephone follow-up and registration.
Yu Liu
Liu Yu is responsible for providing the ideas of this article, overall coordination of everyone's division of labor, and finalization of the final article.